Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab first-in-human phase 1/2 study in relapsed or refractory multiple myeloma
2024-511454-45-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label trial of linvoseltamab in multiple myeloma (MM) (5 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of dose-limiting toxicities, Treatment-emergent adverse events and 5 more. Planned start Aug 2024; status: authorised.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-511454-45-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511454-45-00.